CyFlow CD180 Low Endotoxin
品番 | CP389435 | ||
---|---|---|---|
抗体名 | Anti-Hu CD180 LOW END,G28-8 | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG1 Low Endotoxin (AK478344) |
||
反応性|交差吸着 | Human | レーザー | |
抗原 | CD180, RP105, Bgp95, Ly64 | 最大蛍光波長 | - |
クローン | G28-8 | 最大励起波長 | - |
ホスト | Mouse | 標識/Format | Low Endotoxin |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD180 LOW END,G28-8
特異性
The mouse monoclonal antibody G28-8 recognizes CD180 antigen, a 95-105 kDa TLR-like glycoprotein expressed on peripheral blood monocytes and dendritic cells, mantle zone B cells and marginal zone B cells, but very weakly on germinal center B cells.
抗原情報
CD180 (RP105, Bgp95, LY64) is a type I membrane glycoprotein of Toll-like receptor (TLR) family. Its cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation of CD80/CD86, and increase in cell size.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, Valentine MA: Activation of human B cells: Comparison of the signal transduced by IL‑4 to fourdifferent competence signals. J·Immunol. 1989·Dec·15; 143(12):3873‑80. <·PMID:·2480376·>
• Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL: Negative regulation of Toll‑like receptor 4 signaling by the Toll‑like receptor homolog RP105. Nat·Immunol. 2005·Jun; 6(6):571‑8. <·PMID:·15852007·>
• Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J·Leukoc·Biol. 2007·Aug; 82(2):265‑71. <·PMID:·17470533·>
• Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann·Rheum·Dis. 2001·Dec; 60(12):1137‑40. <·PMID:·11709456·>
• Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA: Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J·Immunol. 2003·Jun·15; 170(12):6065‑72. <·PMID:·12794135·>
• Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA: Antibody to a novel 95‑kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J·Immunol. 1988·Jun·15; 140(12):4071‑8. <·PMID:·3259604·>
• Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the toll‑like receptor RP105 signaling in B lymphocytes. Blood. 2003·Aug·15; 102(4):1374‑80. <·PMID:·12714520·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN